WWARN's Clinical Group has published results supporting the need for a radical cure strategy to tackle one of the most debilitating forms of malaria caused by the Plasmodium vivax parasite.

The WWARN network is very saddened by the news of the passing of Prof Ogobara Doumbo on Saturday 9 June in Marseille, France. Prof Doumbo was a long-standing WWARN partner and highly respected for his contribution to the malaria community through co-founding the Centre for Malaria Research & Trainin...

WWARN’s Clinical Group led by Professor Ric Price joined government ministers, international institutes, malaria experts and civil society organisations in Melbourne Australia for the First Malaria World Congress 1-5 July 2018. Discussions focussed on elimination efforts, cross-sectoral collaboratio...

Current recommended treatment regimens for the most widely used medicine for uncomplicated Plasmodium falciparum malaria may be sub-optimal for small children and pregnant women according to a study led by Prof. Joel Tarning, Head of Pharmacometrics at the WorldWide Antimalarial Resistance Network (...

A pioneering conference will bring leading professionals from all over the world to Oxford, UK to discuss strategies for tackling poor quality medical products on a global scale.

The World Health Organization (WHO) recommended in 2012 to add single low-dose primaquine (SLDPQ) to standard artemisinin based combination treatments (ACTs) to block the transmission of Plasmodium falciparum malaria. The target dose of 0.25 mg base/kg body weight (15 mg in a 60 kg adult) was consid...

The Commonwealth Malaria Summit last week in London (part of CHOGM 2018) welcomed Bill Gates and 12 Heads of State, 2 Deputy Heads of State and many international organisations on Wednesday 18th April. This fantastic event resulted in more than £2.9bn / $4.1bn pledged from Governments, the private s...

We had a fantastic time at the Multilateral Initiative on Malaria’s 7th Pan-African meeting in Dakar, Senegal, 15-20 April, 2018. Thank you for joining us!

Children suffering from malaria and malnutrition might experience diminished height growth when treated for both conditions simultaneously, according to a recently published article.

A new study published today reveals the challenges of establishing sustainable and effective networks to tackle resistance to antimicrobial medicines in low- and middle-income countries (LMICs).

The fourth Quality of Medical Products and Public Health course will take place in Oxford this year, from 17-21 September, at Wolfson College. This multidisciplinary course is aimed at professionals who are interested in the quality of medical products. The application deadline is 18 May.

Two new WHO publications highlight the prevalence and impact of substandard and falsified medical products. An estimated 1 in 10 medical products circulating in low- and middle-income countries is either substandard or falsified, according to new research from the World Health Organization (WHO).

New literature review on soil-transmitted helminths provides compelling evidence for the need to develop a data sharing platform to monitor and improve treatment outcomes for this neglected tropical disease.

The IDDO team will be attending this year’s American Society of Tropical Medicine and Hygiene (ASTMH) Annual Meeting held in Baltimore, USA. Visit the Centre for Tropical Medicine & Global Health booth (number 312) in the exhibition area to meet staff members.

The IDDO and Be-cause health Medicine Quality teams will be addressing the issue of poor quality medicines at the forthcoming European Congress on Tropical Medicine and International Health (ECTMIH) in Antwerp, Belgium.

The WorldWide Antimalarial Resistance Network (WWARN) has been shortlisted for a 2017 Times Higher Education (THE) Award in the ‘International Collaboration of the Year’ category.

Combining patient data from visceral leishmaniasis (VL) clinical trials would give scientists and clinicians more tools to understand and treat the disease which can be fatal if untreated.

The World Health Assembly has agreed new terminology that aims to establish a common understanding of key terms used to describe poor quality medical products.

A pioneering academic conference will bring together, for the first time, people from all over the world dealing with the problem of poor quality medicines and their impact on public health.

The third Quality of Medical Products and Public Health course will take place in Boston, USA this year, from 10-14 July. The course is a pioneering initiative developed by the London School of Hygiene & Tropical Medicine and the University of Oxford.